Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 14/20 | 0.68 |
| ▸ | CDK6 | Q00534 | 12/20 | 0.68 |
| ▸ | CCND1 | P24385 | 10/20 | 0.68 |
| ▸ | TTK | P33981 | 2/20 | 0.62 |
| ▸ | PLK1 | P53350 | 1/20 | 0.62 |
| ▸ | CCNA2 | P20248 | 5/20 | 0.57 |
| ▸ | CDK2 | P24941 | 2/20 | 0.57 |
| ▸ | CCND3 | P30281 | 8/20 | 0.55 |
| ▸ | CCND2 | P30279 | 2/20 | 0.55 |
| ▸ | CDK9 | P50750 | 4/20 | 0.51 |
| ▸ | CCNK | O75909 | 2/20 | 0.51 |
| ▸ | CDK1 | P06493 | 4/20 | 0.50 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.50 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.49 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.49 |
| ▸ | CDK7 | P50613 | 1/20 | 0.49 |
| ▸ | CCNH | P51946 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11984270 | 0.89 | CDK4 (0.61) | CDK4CDK6CCND1TTKPLK1 | |
| SCHEMBL13616064 | 0.88 | CDK4 (0.61) | CDK4CDK6CCND1CCNA2CDK2 | |
| SCHEMBL14681895 | 0.84 | CDK4 (0.55) | CDK4CDK6CCND1TTKPLK1 | |
| SCHEMBL20959575 | 0.81 | CDK4 (1.00) | CDK4CDK6CCND1TTKPLK1 | |
| SCHEMBL23713691 | 0.79 | CDK4 (0.63) | CDK4CDK6CCND1TTKPLK1 | |
| SCHEMBL13616794 | 0.78 | CDK6 (0.53) | CDK4CDK6CCND1CCNA2CDK2 | |
| SCHEMBL17194091 | 0.78 | CDK4 (0.74) | CDK4CDK6CCND1TTKPLK1 | |
| SCHEMBL7715006 | 0.78 | CDK4 (0.76) | CDK4CDK6CCND1TTKCCNA2 | |
| SCHEMBL22165717 | 0.77 | CDK4 (0.63) | CDK4CDK6CCND1TTKPLK1 | |
| SCHEMBL616945 | 0.77 | TTK (1.00) | CDK4CDK6CCND1TTKPLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318441-A1 | Pyrrolopyrimidine Compounds and Their Uses | ASTEX THERAPEUTICS LTD. | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318441-A1 | Pyrrolopyrimidine Compounds and Their Uses | PRKDC, TK2, PNKP | CDK4 4/4885CDK6 28/4885CCND1 615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.